Hugging Face's logo

Datasets:
AI4Pathology
/
ImmunoBench-image-features

Tasks:
Feature Extraction
Modalities:
Image
Formats:
imagefolder
Languages:
English
Size:
< 1K
Tags:
medical-imaging
computational-pathology
digital-pathology
immunohistochemistry
foundation-model
pan-cancer
Libraries:
Datasets
License:
Dataset card Data Studio Files
xet
 Community

You need to agree to share your contact information to access this dataset

This repository is publicly accessible, but you have to accept the conditions to access its files and content.

Log in or Sign Up to review the conditions and access this dataset content.

ImmunoBench Feature Representations

🔍 Overview

🤗 Dataset | 🌐 Homepage | 📄 Paper (coming soon) | 💻 Code

This repository provides pre-extracted feature representations from whole slide images (WSIs) from the ImmunoBench project, a large-scale benchmark designed for evaluating pathology foundation models in IHC-centered pathology workflows. ImmunoBench integrates data from 13,657 patients, 26,058 WSIs, 9,682,431 TMA-derived IHC images and 464,294 annotated patches, collected across 13 institutions, covering 27 organs, 43 clinical stains and 14,708 gene-encoded proteins.

Figure 1. ImmunoBench dataset overview Figure 2. ImmunoBench task taxonomy

📚 Contents

  • Overview
  • Access Policy
  • Dataset Versioning and Updates
  • Usage Notes
  • Contributions
  • Contact
  • Task-Dataset Mapping (Category 1-6)
  • Citation

🔒 Access Policy

Access to this dataset is restricted and subject to approval.

To request access:

  • Please contact the dataset maintainers using your institutional email address
  • Clearly state your affiliation, research purpose, and intended use

⚠️ This dataset is provided for academic research only.
Commercial use is strictly prohibited without prior written permission.

🔄 Dataset Versioning & Updates

This dataset is part of an actively maintained benchmark and will be continuously updated.

  • Future releases may include:
    • Additional cohorts
    • More foundation models
    • Extended feature modalities

All updates will be documented in this repository and the project homepage: 🌐 Project Homepage

⚠️ Usage Notes

  • These features are pre-extracted representations, not raw images
  • Performance may vary depending on downstream task design
  • Users are responsible for ensuring compliance with local data regulations

🤝 Contributions

We welcome community contributions and collaborations.

If you would like to propose additional datasets, tasks, or benchmark extensions for inclusion in ImmunoBench, please contact us or open an issue in our GitHub repository.

💻 GitHub Issues

📫 Contact

For access requests, collaboration inquiries, or technical issues:

📧 test@pjlab.org.cn

🧭 Task-Dataset Mapping (41 Datasets -> 71 Tasks)

ImmunoBench organizes 71 benchmark tasks derived from 41 source datasets. The mapping is one-to-many: one dataset can support multiple tasks.

Category 1: Immunohistochemical Staining Assessment

This category contains 3 TMA-image-level tasks from HPA10M, focused on expression-related staining characteristics.

  1. Staining Intensity (HPA10M) — Level: TMA images; Classes: 4
  2. Staining Location (HPA10M) — Level: TMA images; Classes: 4
  3. Staining Quantity (HPA10M) — Level: TMA images; Classes: 4
Detailed Metadata (Category 1)

  • Staining Intensity: Level = TMA images; 3,433 patients, 9,682,431 images; classes = Moderate, Weak, Strong, None; stain = 9,682,431 gene-encoded protein labels; tissue site = 25 tissues (organ-level mapping).

  • Staining Location: Level = TMA images; 3,433 patients, 9,682,431 images; classes = Cytoplasmic/membranous, Nuclear, Cytoplasmic/membranous and nuclear, None; stain = 9,682,431 gene-encoded protein labels; tissue site = 25 tissues (organ-level mapping).

  • Staining Quantity: Level = TMA images; 3,433 patients, 9,682,431 images; classes = >75%, 25%-75%, <25%, None; stain = 9,682,431 gene-encoded protein labels; tissue site = 25 tissues (organ-level mapping).

  • Organ-level mapping (25 tissue categories): Lung, Breast, Uterus, Ovary, Cervix, Prostate, Testis, Kidney, Bladder, Intestine, Stomach, Pancreas, Liver, Gallbladder and Bile Duct, Thyroid, Adrenal Gland, Skin, Muscle and Soft Tissue, Heart, Spleen, Lymph Gland, Nervous System, Hematopoietic and Lymphatic System, Ear, Nose, Throat and Oral Cavity, Vulva and Vagina.

Category 2: Immunohistochemical Biomarker Expression Prediction

This category contains 33 tasks, including 25 WSI-level tasks and 8 patch-level tasks.

  1. PanCa-GATA3 (PANCA-GATA3) — Level: WSI; Classes: 2
  2. PanCa-CDX2 (PANCA-CDX2) — Level: WSI; Classes: 2
  3. PanCa-TTF1 (PANCA-TTF1) — Level: WSI; Classes: 2
  4. PanCa-P40 (PANCA-P40) — Level: WSI; Classes: 2
  5. PanCa-PAX8 (PANCA-PAX8) — Level: WSI; Classes: 2
  6. PanCa-CK5/6 (PANCA-CK56) — Level: WSI; Classes: 2
  7. PanCa-P63 (PANCA-P63) — Level: WSI; Classes: 2
  8. PanCa-CK7 (PANCA-CK7) — Level: WSI; Classes: 2
  9. PanCa-PSA (PANCA-PSA) — Level: WSI; Classes: 2
  10. PanCa-NapsinA (PANCA-NAPSINA) — Level: WSI; Classes: 2
  11. PanCa-P53 (PANCA-P53) — Level: WSI; Classes: 2
  12. PanCa-P16 (PANCA-P16) — Level: WSI; Classes: 2
  13. PanCa-Ki67 (PANCA-Ki67) — Level: WSI; Classes: 9
  14. PanCa-SYN (PANCA-SYN) — Level: WSI; Classes: 2
  15. PanCa-S100 (PANCA-S100) — Level: WSI; Classes: 2
  16. PanCa-CD34 (PANCA-CD34) — Level: WSI; Classes: 2
  17. PanCa-D2-40 (PANCA-D2-40) — Level: WSI; Classes: 2
  18. PanCa-AR (PANCA-AR) — Level: WSI; Classes: 2
  19. PanCa-PR (PANCA-PR) — Level: WSI; Classes: 2
  20. PanCa-ER (PANCA-ER) — Level: WSI; Classes: 2
  21. PanCa-PD-L1 (PANCA-PD-L1) — Level: WSI; Classes: 2
  22. Lymphoma-CD20 (Lymph-CD20) — Level: WSI; Classes: 2
  23. Lymphoma-CD10 (Lymph-CD10) — Level: WSI; Classes: 2
  24. Lymphoma-BCL2 (Lymph-BCL2) — Level: WSI; Classes: 2
  25. Lymphoma-EBER (Lymph-EBER) — Level: WSI; Classes: 2
  26. Breast-HER2 (BCI) — Level: Patch; Classes: 4
  27. Breast-ER (IHC4BC) — Level: Patch; Classes: 4
  28. Breast-PR (IHC4BC) — Level: Patch; Classes: 4
  29. Breast-Ki67 (IHC4BC) — Level: Patch; Classes: 5
  30. Breast-H&E-to-HER2 (BCI) — Level: Patch; Classes: 4
  31. Breast-H&E-to-ER (IHC4BC) — Level: Patch; Classes: 4
  32. Breast-H&E-to-PR (IHC4BC) — Level: Patch; Classes: 4
  33. Breast-H&E-to-Ki67 (IHC4BC) — Level: Patch; Classes: 5
Detailed Metadata (Category 2)
  • PanCa-GATA3: Level = WSI; 285 patients, 285 WSIs; classes = Positive, Negative; stain = GATA3; external test = Yes (External-PanCa-GATA3); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-CDX2: Level = WSI; 165 patients, 165 WSIs; classes = Positive, Negative; stain = CDX2; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-TTF1: Level = WSI; 246 patients, 246 WSIs; classes = Positive, Negative; stain = TTF1; external test = Yes (External-PanCa-TTF1); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-P40: Level = WSI; 288 patients, 288 WSIs; classes = Positive, Negative; stain = P40; external test = Yes (External-PanCa-P40); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-PAX8: Level = WSI; 314 patients, 314 WSIs; classes = Positive, Negative; stain = PAX8; external test = Yes (External-PanCa-PAX8); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-CK5/6: Level = WSI; 252 patients, 252 WSIs; classes = Positive, Negative; stain = CK56; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-P63: Level = WSI; 257 patients, 257 WSIs; classes = Positive, Negative; stain = P63; external test = Yes (External-PanCa-P63); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-CK7: Level = WSI; 192 patients, 192 WSIs; classes = Positive, Negative; stain = CK7; external test = Yes (External-PanCa-CK7); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-PSA: Level = WSI; 124 patients, 124 WSIs; classes = Positive, Negative; stain = PSA; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-NapsinA: Level = WSI; 238 patients, 238 WSIs; classes = Positive, Negative; stain = NapsinA; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-P53: Level = WSI; 226 patients, 226 WSIs; classes = Wild-type expression, Mutant expression; stain = P53; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-P16: Level = WSI; 297 patients, 297 WSIs; classes = Positive, Negative; stain = P16; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-Ki67: Level = WSI; 568 patients, 568 WSIs; classes = Ki67 labeling index is 10-90% (10% intervals); stain = Ki67; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-SYN: Level = WSI; 275 patients, 275 WSIs; classes = Positive, Negative; stain = SYN; external test = Yes (External-PanCa-SYN); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-S100: Level = WSI; 262 patients, 262 WSIs; classes = Positive, Negative; stain = S100; external test = Yes (External-PanCa-S100); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-CD34: Level = WSI; 464 patients, 464 WSIs; classes = Positive, Negative; stain = CD34; external test = Yes (External-PanCa-CD34); tissue site = Multi-organ pan-cancer cohort.
  • PanCa-D2-40: Level = WSI; 228 patients, 228 WSIs; classes = Positive, Negative; stain = D2-40; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-AR: Level = WSI; 303 patients, 303 WSIs; classes = Positive, Negative; stain = AR; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-PR: Level = WSI; 222 patients, 225 WSIs; classes = Positive, Negative; stain = PR; external test = No; tissue site = Multi-organ pan-cancer cohort.
  • PanCa-ER: Level = WSI; 224 patients, 226 WSIs; classes = Positive, Negative; stain = ER; external test = No; tissue site = Breast.
  • PanCa-PD-L1: Level = WSI; 163 patients, 163 WSIs; classes = Positive, Negative; stain = PD-L1; external test = Yes (External-PanCa-PD-L1); tissue site = Multi-organ pan-cancer cohort.
  • Lymphoma-CD20: Level = WSI; 272 patients, 272 WSIs; classes = Positive, Negative; stain = CD20; external test = Yes (External-PanCa-CD20); tissue site = Lymph gland.
  • Lymphoma-CD10: Level = WSI; 209 patients, 209 WSIs; classes = Positive, Negative; stain = CD10; external test = Yes (External-PanCa-CD10); tissue site = Lymph gland.
  • Lymphoma-BCL2: Level = WSI; 159 patients, 159 WSIs; classes = Positive, Negative; stain = Bcl-2; external test = No; tissue site = Lymph gland.
  • Lymphoma-EBER: Level = WSI; 234 patients, 234 WSIs; classes = Positive, Negative; stain = EBER; external test = No; tissue site = Lymph gland.
  • Breast-HER2: Level = Patch; patients = -, WSIs = 600 (4,873 patches); classes = 0, 1+, 2+, 3+; stain = IHC; external test = No; tissue site = Breast.
  • Breast-ER: Level = Patch; 59 patients, WSIs = 240 (26,130 patches); classes = 0, 1+, 2+, 3+; stain = ER; external test = No; tissue site = Breast.
  • Breast-PR: Level = Patch; 60 patients, WSIs = 240 (24,971 patches); classes = 0, 1+, 2+, 3+; stain = PR; external test = No; tissue site = Breast.
  • Breast-Ki67: Level = Patch; 60 patients, WSIs = 240 (20,656 patches); classes = Low, intermediate-low, intermediate-high, high Ki67 labeling index; stain = Ki67; external test = No; tissue site = Breast.
  • Breast-H&E-to-HER2: Level = Patch; patients = -, WSIs = 600 (4,873 patches); classes = 0, 1+, 2+, 3+; stain = H&E; external test = No; tissue site = Breast.
  • Breast-H&E-to-ER: Level = Patch; 59 patients, WSIs = 240 (26,130 patches); classes = 0, 1+, 2+, 3+; stain = ER; external test = No; tissue site = Breast.
  • Breast-H&E-to-PR: Level = Patch; 60 patients, WSIs = 240 (24,971 patches); classes = 0, 1+, 2+, 3+; stain = PR; external test = No; tissue site = Breast.
  • Breast-H&E-to-Ki67: Level = Patch; 60 patients, WSIs = 240 (20,656 patches); classes = Low, intermediate-low, intermediate-high, high Ki67 labeling index; stain = Ki67; external test = No; tissue site = Breast.

Category 3: Disease Diagnosis and Grading

  1. Lymphoma-Subtype (Lymph-SUB) — Level: WSI; Classes: 4
  2. Testis-pT (HE-Ki67) — Level: WSI; Classes: 2
  3. HNSCC-Histotype (HANCOCK) — Level: WSI; Classes: 4
  4. HNSCC-Histology (HANCOCK) — Level: WSI; Classes: 3
  5. Testis-infiltration-Pattern (HE-Ki67) — Level: WSI; Classes: 2
  6. Cervix-CIN (CERVIX-CIN) — Level: WSI; Classes: 3
Detailed Metadata (Category 3)
  • Lymphoma-Subtype: 320 patients, 1,875 WSIs; classes = NK-T, FL, DLBCL, AITL; stain = CD5, EBER, CD21, CD79a, CD3, CD20, H&E; tissue site = Hematopoietic and Lymphatic System.
  • Testis-pT: 72 patients, 144 WSIs; classes = pT1 stage, pT2 stage; stain = Ki67, H&E; tissue site = Testis.
  • HNSCC-Histotype: 706 patients, 706 WSIs; classes = Keratinizing SCC, Non-keratinizing SCC, Basaloid SCC, Other histologic subtypes; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Histology: 593 patients, 593 WSIs; classes = Grade 1, Grade 2, Grade 3; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • Testis-infiltration-Pattern: 77 patients, 154 WSIs; classes = Infiltrative pattern, Non-infiltrative pattern; stain = Ki67, H&E; tissue site = Testis.
  • Cervix-CIN: 175 patients, 488 WSIs; classes = CIN 1, CIN 2, CIN 3; stain = P16, Ki67, H&E; tissue site = Cervix.

Category 4: Tissue Composition and Microenvironment Segmentation

This category contains 10 patch-level tissue composition tasks from HNSCC and MIHIC cohorts.

  1. HNSCC-Comp (HNSCC) — Level: Patch; Classes: 3
  2. HNSCC-Comp(CD8+) (HNSCC) — Level: Patch; Classes: 3
  3. HNSCC-Comp(FoxP3+) (HNSCC) — Level: Patch; Classes: 3
  4. HNSCC-Comp(CD3+) (HNSCC) — Level: Patch; Classes: 3
  5. HNSCC-Comp(H&E) (HNSCC) — Level: Patch; Classes: 3
  6. HNSCC-Comp(PanCK+) (HNSCC) — Level: Patch; Classes: 3
  7. Lung-Comp (MIHIC) — Level: Patch; Classes: 7
  8. Lung-Comp(SMA+) (MIHIC) — Level: Patch; Classes: 6
  9. Lung-Comp(CD3+) (MIHIC) — Level: Patch; Classes: 7
  10. Lung-Comp(CD38+) (MIHIC) — Level: Patch; Classes: 6
Detailed Metadata (Category 4)
  • HNSCC-Comp: Level = Patch; 8 patients, 1,336 patches; classes = Tumor core, Invasive margin, Adjacent stroma; stain = HEMATOXYLIN, PCK, CD3, CD8, FOXP3; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Comp(CD8+): Level = Patch; 8 patients, 264 patches; classes = Tumor core, Invasive margin, Adjacent stroma; stain = CD8; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Comp(FoxP3+): Level = Patch; 8 patients, 268 patches; classes = Tumor core, Invasive margin, Adjacent stroma; stain = FOXP3; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Comp(CD3+): Level = Patch; 8 patients, 268 patches; classes = Tumor core, Invasive margin, Adjacent stroma; stain = CD3; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Comp(H&E): Level = Patch; 8 patients, 268 patches; classes = Tumor core, Invasive margin, Adjacent stroma; stain = HEMATOXYLIN; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Comp(PanCK+): Level = Patch; 8 patients, 268 patches; classes = Tumor core, Invasive margin, Adjacent stroma; stain = PCK; tissue site = Ear, Nose, Throat and Oral Cavity.
  • Lung-Comp: Level = Patch; 18 patients, 309,698 patches; classes = Immune cells, Necrosis, Stroma, Tumor, Alveoli, Background, Other; stain = CD68, CD34, FAP, P53, CYCLIN, CD3, D2, CDK4, SMA, CD38, CD20, Ki67; tissue site = Lung.
  • Lung-Comp(SMA+): Level = Patch; 13 patients, 18,589 patches; classes = Immune cells, Necrosis, Stroma, Tumor, Alveoli, Other; stain = SMA; tissue site = Lung.
  • Lung-Comp(CD3+): Level = Patch; 17 patients, 34,952 patches; classes = Immune cells, Necrosis, Stroma, Tumor, Alveoli, Background, Other; stain = CD3; tissue site = Lung.
  • Lung-Comp(CD38+): Level = Patch; 17 patients, 23,729 patches; classes = Immune cells, Necrosis, Stroma, Tumor, Alveoli, Other; stain = CD38; tissue site = Lung.

Category 5: Disease Progression and Prognosis

This category contains 9 WSI-level time-to-event prediction tasks, evaluated by C-index.

  1. HNSCC-Surg-OS (HANCOCK) — Level: WSI; Endpoint: OS
  2. HNSCC-Surg-DSS (HANCOCK) — Level: WSI; Endpoint: DSS
  3. HNSCC-RT-OS (HANCOCK) — Level: WSI; Endpoint: OS
  4. HNSCC-RT-DSS (HANCOCK) — Level: WSI; Endpoint: DSS
  5. HNSCC-CT-OS (HANCOCK) — Level: WSI; Endpoint: OS
  6. HNSCC-CT-DSS (HANCOCK) — Level: WSI; Endpoint: DSS
  7. Lymphoma-OS (DLBCL-Morph) — Level: WSI; Endpoint: OS
  8. Lung-PFS (MSKMINDProjectM) — Level: WSI; Endpoint: PFS
  9. Uterus-OS (InUIT) — Level: WSI; Endpoint: OS
Detailed Metadata (Category 5)
  • HNSCC-Surg-OS: Level = WSI; 276 patients, 3,974 WSIs; survival endpoint = Overall survival (OS); stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Surg-DSS: Level = WSI; 276 patients, 3,974 WSIs; survival endpoint = Disease-specific survival (DSS); stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-RT-OS: Level = WSI; 448 patients, 6,324 WSIs; survival endpoint = Overall survival (OS); stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-RT-DSS: Level = WSI; 448 patients, 6,324 WSIs; survival endpoint = Disease-specific survival (DSS); stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-CT-OS: Level = WSI; 286 patients, 3,973 WSIs; survival endpoint = Overall survival (OS); stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-CT-DSS: Level = WSI; 286 patients, 3,973 WSIs; survival endpoint = Disease-specific survival (DSS); stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • Lymphoma-OS: Level = WSI; 170 patients, 1,009 WSIs; survival endpoint = Overall survival (OS); stain = MUM1, CD10, BCL2, BCL6, MYC, H&E; tissue site = Hematopoietic and Lymphatic System.
  • Lung-PFS: Level = WSI; 212 patients, 212 WSIs; survival endpoint = Progression-free survival (PFS); stain = PD-L1; tissue site = Lung.
  • Uterus-OS: Level = WSI; 204 patients, 1,481 WSIs; survival endpoint = Overall survival (OS); stain = CD8, CD20, Ki67; tissue site = Uterus.

Category 6: Treatment Response, Metastasis, and Recurrence

This category contains 10 WSI-level clinical outcome tasks across surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy settings.

  1. HNSCC-Surg-Met (HANCOCK) — Treatment: Surgery; Level: WSI; Classes: 2
  2. HNSCC-Surg-Rec (HANCOCK) — Treatment: Surgery; Level: WSI; Classes: 2
  3. HNSCC-RT-Met (HANCOCK) — Treatment: Radiotherapy; Level: WSI; Classes: 2
  4. HNSCC-RT-Rec (HANCOCK) — Treatment: Radiotherapy; Level: WSI; Classes: 2
  5. HNSCC-CT-Met (HANCOCK) — Treatment: Chemotherapy; Level: WSI; Classes: 2
  6. HNSCC-CT-Rec (HANCOCK) — Treatment: Chemotherapy; Level: WSI; Classes: 2
  7. Breast-TNBC-pCR (IMPRESS-DATA) — Treatment: Chemotherapy; Level: WSI; Classes: 2
  8. Breast-RCB (BREAST-RCB) — Treatment: Neoadjuvant Chemotherapy; Level: WSI; Classes: 4
  9. Breast-HER2-pCR (IMPRESS-DATA) — Treatment: Targeted Therapy (Trastuzumab); Level: WSI; Classes: 2
  10. Lung-Immunotherapy (MSKMINDProjectM) — Treatment: Immunotherapy; Level: WSI; Classes: 2
Detailed Metadata (Category 6)
  • HNSCC-Surg-Met: Treatment method = Surgery; Level = WSI; 276 patients, 3,974 WSIs; classes = Metastatic, Non-metastatic; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-Surg-Rec: Treatment method = Surgery; Level = WSI; 276 patients, 3,974 WSIs; classes = Recurrence, Non-recurrence; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-RT-Met: Treatment method = Radiotherapy; Level = WSI; 448 patients, 6,324 WSIs; classes = Metastatic, Non-metastatic; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-RT-Rec: Treatment method = Radiotherapy; Level = WSI; 448 patients, 6,324 WSIs; classes = Recurrence, Non-recurrence; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-CT-Met: Treatment method = Chemotherapy; Level = WSI; 286 patients, 3,973 WSIs; classes = Metastatic, Non-metastatic; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • HNSCC-CT-Rec: Treatment method = Chemotherapy; Level = WSI; 286 patients, 3,973 WSIs; classes = Recurrence, Non-recurrence; stain = MHC1, CD68, CD3, CD163, PD-L1, CD56, CD8, H&E; tissue site = Ear, Nose, Throat and Oral Cavity.
  • Breast-TNBC-pCR: Treatment method = Chemotherapy; Level = WSI; 60 patients, 115 WSIs; classes = Non-pathological complete response (non-pCR), Pathological complete response (pCR); stain = Multiplex IHC (PD-L1, CD8, CD163), H&E; tissue site = Breast.
  • Breast-RCB: Treatment method = Neoadjuvant Chemotherapy; Level = WSI; 87 patients, 440 WSIs; classes = RCB-0, RCB-I, RCB-II, RCB-III; stain = PR, HER2, ER, GATA3, Ki67, H&E; tissue site = Breast.
  • Breast-HER2-pCR: Treatment method = Targeted Therapy (Trastuzumab); Level = WSI; 45 patients, 79 WSIs; classes = Non-pathological complete response (non-pCR), Pathological complete response (pCR); stain = Multiplex IHC (PD-L1, CD8, CD163), H&E; tissue site = Breast.
  • Lung-Immunotherapy: Treatment method = Immunotherapy; Level = WSI; 212 patients, 212 WSIs; classes = PD-L1 Immunotherapy Responder, Non-responder; stain = PD-L1; tissue site = Lung.

📖 Citation

If you use this dataset in your research, please cite:

[Citation information coming soon.]
Downloads last month
168
Total file size:
757 GB